In an effort toward the research and development of new and potentially breakthrough treatment options for patients with congestive heart failure, DMC Cardiovascular Institute has become the first hospital in Michigan and the seventh hospital across the United States to participate in the INOVATE-HF (INcrease Of VAgal TonE Heart Failure) clinical trial.
Henry Ford Hospital’s Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma, a fast-growing brain cancer that often recurs even after surgery, radiation treatment and chemotherapy.
Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had started a Phase II clinical trial of Trimesta (oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis in women.
CytoPherx Inc. announced it has completed a $34 million round of funding. The funds will be used to complete United States clinical trials and gain FDA approval to commercialize the CytoPherx anti-inflammatory therapy for acute kidney injury.
Adeona Pharmaceuticals Inc. said Monday that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta oral estriol drug candidate for relapsing-remitting multiple sclerosis in women.
Grand Rapids-based Spectrum Health is participating in a clinical trial to evaluate a transcatheter alternative to open-heart surgery for patients with severe aortic stenosis.
Building upon a series of successful preclinical and clinical studies, Ann Arbor-based NanoBio Corp. Tuesday announced the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant.
Michigan is one of 10 states where the 600 patients are being drawn from for Pfizer Inc.’s first-ever virtual clinical trial. The trial model allows patients to participate regardless of geography.
Battle Creek-based Brookside Surgery Center said one of its surgeons, Joseph Burkhardt, is participating in a 10-year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee
Kalamazoo-based Metabolic Solutions Development Co., a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced Tuesday that it has launched a Phase 2a trial for MSDC-0602, the company’s second drug candidate for the treatment of type 2 diabetes.